Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded ...

Top cancer scientists, former NIH leaders, and patient advocates warned that the Trump administration's cuts to science ...

Immunic's MS drug shows 20% risk reduction vs placebo; Entrada cuts jobs; Henlius-Sandoz deal; Cellectar explores options; ...

GSK said its decoupling with Haleon is a key reason why it views itself as “well-positioned” in the face of potential ...

Novartis to acquire Regulus Therapeutics for $7/share with potential $7 CVR tied to farabursen approval. Deal values Regulus ...

Noma Therapy, a virtual ketamine-assisted therapy provider, has launched with $4.25 million in funding, Endpoints News ...

BridgeBio's Attruby exceeds Q1 forecasts with $36.7M in sales, 2,072 prescriptions. CEO Neil Kumar credits clinical data; ...

Artios Pharma, a startup developing drugs that weaken a tumor’s ability to maintain its DNA, announced positive results in a ...

Pfizer CEO Albert Bourla gave an optimistic read on Tuesday when asked how he thought the trade levies might be implemented.

Octagon Therapeutics, led by CEO Isaac Stoner, is shutting down after halting work on B cell immunomodulator and facing ...

The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the ...

In an unlikely partnership between two rivals, Hims & Hers said its members will now be able to get Novo Nordisk’s weight ...